| Name | Title | Contact Details |
|---|
SetPoint Medical is developing novel neuromodulation therapies to treat those who suffer from inflammatory diseases such as Crohn`s Disease and rheumatoid arthritis. The company is developing a proprietary and innovative neuromodulation therapy delivery platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy will provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payors less than 50% of what today`s leading biologic therapies cost.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Proprio is a Seattle company developing a system for real-time immersive video and mediated reality interaction. We are using cutting edge algorithms and custom hardware to enhance human capabilities in high precision activities such as brain surgery.
inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries. The Company operates in four segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. The Company supports a range of clinical development, communications and commercialization activities that are critical to its customers' ability to complete the development of drug products and medical devices and commercialize them. In addition, the Company provides medical cost containment services to payors in its patient outcomes business. inVentiv provides services to over 350 client organizations, including global pharmaceutical companies, emerging and specialty biotechnology companies, and payors.
To be Hansei is to reflect on the past, learn from mistakes, and commit to doing better in the future. To stop Hansei is to stop learning. Hansei Solutions helps behavioral healthcare facilities nationwide do it better, combining full-service revenue cycle management technology with a personal touch to forge lasting and strategic partnerships. Simply put, Hansei enables providers to collect more, save more, remain compliant, and make more informed decisions impacting their growth and bottom line.